Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sangamo Therapeutics (SGMO) EBITDA Margin (2016 - 2025)

Sangamo Therapeutics has reported EBITDA Margin over the past 16 years, most recently at 268.51% for Q4 2025.

  • Quarterly results put EBITDA Margin at 268.51% for Q4 2025, up 13134.0% from a year ago — trailing twelve months through Dec 2025 was 306.53% (down 12332.0% YoY), and the annual figure for FY2025 was 306.53%, down 12665.0%.
  • EBITDA Margin for Q4 2025 was 268.51% at Sangamo Therapeutics, up from 6119.28% in the prior quarter.
  • Over the last five years, EBITDA Margin for SGMO hit a ceiling of 21.52% in Q3 2024 and a floor of 10712.27% in Q1 2024.
  • Median EBITDA Margin over the past 5 years was 207.46% (2022), compared with a mean of 1877.28%.
  • Biggest five-year swings in EBITDA Margin: plummeted -1072368bps in 2024 and later skyrocketed 1031932bps in 2025.
  • Sangamo Therapeutics' EBITDA Margin stood at 169.58% in 2021, then decreased by -20bps to 203.42% in 2022, then tumbled by -1394bps to 3039.13% in 2023, then soared by 87bps to 399.85% in 2024, then soared by 33bps to 268.51% in 2025.
  • The last three reported values for EBITDA Margin were 268.51% (Q4 2025), 6119.28% (Q3 2025), and 97.54% (Q2 2025) per Business Quant data.